Man Group plc Takes $7.16 Million Position in Sarepta Therapeutics, Inc. $SRPT

Man Group plc acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 398,144 shares of the biotechnology company’s stock, valued at approximately $7,155,000. Man Group plc owned approximately 0.38% of Sarepta Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. bought a new position in Sarepta Therapeutics during the 2nd quarter valued at about $341,339,000. Vanguard Group Inc. grew its stake in Sarepta Therapeutics by 9.2% during the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after buying an additional 993,283 shares during the last quarter. AQR Capital Management LLC grew its stake in Sarepta Therapeutics by 454.6% during the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after buying an additional 6,390,860 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Sarepta Therapeutics by 107.6% during the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after buying an additional 2,143,211 shares in the last quarter. Finally, Erste Asset Management GmbH increased its holdings in shares of Sarepta Therapeutics by 1.6% during the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock worth $58,727,000 after buying an additional 43,000 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SRPT shares. Wall Street Zen lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Finally, Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Trading Down 3.4%

SRPT opened at $20.86 on Friday. The firm’s fifty day moving average is $17.73 and its two-hundred day moving average is $18.32. The firm has a market cap of $2.20 billion, a PE ratio of -7.19, a price-to-earnings-growth ratio of 0.31 and a beta of 0.23. Sarepta Therapeutics, Inc. has a twelve month low of $14.68 and a twelve month high of $25.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.02 earnings per share. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.